Oral History Review最新文献_第8页

Bronx Faces and Voices: Sixteen Stories of Courage and Community. By Emita Brady Hill and Janet Butler Munch (eds) 布朗克斯的面孔和声音:十六个关于勇气和社区的故事。文/艾米塔·布雷迪·希尔、珍妮特·巴特勒·蒙克(编)

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-04-01 DOI: 10.1093/ohr/ohw092

Laura Kaplan Mercado

引用次数: 0

Breaking the Barrier—PEGylated Recombinant Human Hyaluronidase (PEGPH20)—A New Therapeutic Approach to the Treatment of Pancreatic Ductal Adenocarcinoma 破障聚乙二醇化重组人透明质酸酶(PEGPH20)——治疗胰腺导管腺癌的新方法

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.02.107

A. Hendifar, A. Bullock

{"title":"Breaking the Barrier—PEGylated Recombinant Human Hyaluronidase (PEGPH20)—A New Therapeutic Approach to the Treatment of Pancreatic Ductal Adenocarcinoma","authors":"A. Hendifar, A. Bullock","doi":"10.17925/OHR.2017.13.02.107","DOIUrl":"https://doi.org/10.17925/OHR.2017.13.02.107","url":null,"abstract":"N ew therapeutic approaches are urgently needed to improve survival for patients with metastatic pancreatic ductal adenocarcinoma (PDA). This carcinoma is characterized by a hyaluronan (HA)-rich desmoplastic stroma that raises tumor interstitial fluid pressure (IFP), which in turn compresses the vasculature and impedes access of anti-cancer therapies and immune cells to tumor sites. It is this biophysical barrier that is the target for PEGylated recombinant human hyaluronidase (PEGPH20; pegvorhyaluronidase alfa), which degrades HA polymers to tetraand hexa-saccharides to remodel the tumor stroma. In preclinical models, PEGPH20 reduced IFP, and expanded tumor vasculature to improve perfusion, which increased access for innate immune cells, antibodies and therapeutic agents. The results of a phase Ib study have suggested benefits in overall survival and progression-free survival (PFS) for patients with tumors that accumulate HA (termed HA-High) treated with a combination of gemcitabine and PEGPH20. A phase II study (HALO 109-202) demonstrated that HA could be a potential biomarker for identifying patients who may be most suitable for PEGPH20 treatment. HALO 109-202 showed positive outcomes for PFS especially in HA-High patients treated with PEGPH20 plus nab-paclitaxel and gemcitabine. A randomized, double-blind, phase III study (HALO 109-301) exploring the benefits of PEGPH20 in HA-High patients with PDA is ongoing. Other PEGPH20-based combinations are being investigated in multiple stroma-rich cancers, including lung, gastric, and breast. PEGPH20 is the most advanced therapy targeting the tumor stroma and has the potential to form the therapeutic backbone for the treatment of stroma-rich tumors.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"13 1","pages":"107"},"PeriodicalIF":1.1,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67596735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Monophasic Synovial Sarcoma of the Infratemporal Fossa—Case Report and Review of the Literature 颞下窝单相滑膜肉瘤1例报告及文献复习

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.01.01

Ignacio Mendoza, Ilson Sepúlveda, G. Ayres

引用次数: 0

The Changing Therapeutic Landscape in Metastatic Prostate Cancer 转移性前列腺癌治疗前景的变化

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.02.112

A. Koletsky

{"title":"The Changing Therapeutic Landscape in Metastatic Prostate Cancer","authors":"A. Koletsky","doi":"10.17925/OHR.2017.13.02.112","DOIUrl":"https://doi.org/10.17925/OHR.2017.13.02.112","url":null,"abstract":"O ver the past several years a number of novel and diverse agents have provided a significant clinical benefit for patients with metastatic castration-resistant prostate cancer including abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223. The early use of docetaxel or abiraterone at initiation of standard androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer has also led to substantial improvements in overall survival. The identification of a truncating mutation in the androgen receptor (ARV7), a biomarker of resistance, may help clarify a more optimal sequencing of hormonal and chemotherapy-based therapies for patients with metastatic disease. The genomic landscape of both primary and metastatic prostate cancer has been an important focal point of translational research. The most widely studied pathways that affect tumorigenesis are the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) and poly ADP ribose polymerase (PARP) and DNA repair pathways. This review will highlight recent clinical trials which have had a major impact on the management of patients with metastatic disease with an emphasis on treatments driven by common genomic aberrations present in advanced prostate cancer.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"13 1","pages":"112"},"PeriodicalIF":1.1,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67596751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Developments in the Therapeutic Landscape in Renal Cancer 肾癌治疗前景的最新进展

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.01.15

U. Vaishampayan

引用次数: 0

Raising the Bar in Advanced Pancreatic Cancer 提高晚期胰腺癌的标准

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.01.19

S. Gill

引用次数: 0

Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center? 能否提高甲状腺小容量中心细针穿刺细胞学检查的充分性?

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.01.21

M. Shaaban, M. Metry, S. Aspinall

{"title":"Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center?","authors":"M. Shaaban, M. Metry, S. Aspinall","doi":"10.17925/OHR.2017.13.01.21","DOIUrl":"https://doi.org/10.17925/OHR.2017.13.01.21","url":null,"abstract":"I ntroduction: Thyroid cancer is the most common endocrine malignancy, and has shown an increase in incidence in recent decades. Fine-needle aspiration cytology (FNAC) is the mainstay of assessment of thyroid nodules and diagnosis of malignancy. Several reports have suggested that ultrasound (US)-guided FNAC has many advantages over palpation-guided biopsy. Methods: Comparison of results of thyroid nodule FNACs in a low volume thyroid center (Northumbria Health Care NHS Foundation Trust) performed by a diverse group of clinicians and radiologists involved in the management of thyroid nodules over 18 months, between October 2008 and April 2010, identified retrospectively from pathology records, with the results of surgeon-performed US (SUS) -guided FNACs performed by a single operator (SRA) recorded prospectively over 17 months between July 2013 and November 2014. Results: The study included 185 FNA, with 104 FNAC being undertaken between October 2008 and April 2010 compared to 81 FNAC between July 2013 and November 2014. There was a statistically significant reduction of non-diagnostic rates in the second period: 23/81 (28%) versus 51/104 (49%) (Fisher’s exact, p=0.0063), non-neoplastic (Thy2) scores remained comparable: 28/81 (35%) versus 32/104 (31%), there were more Thy3 results: 21/81 (26%) versus 15/104 (14%), while the proportion of neoplastic results in the SUS-FNAC group increased: 8/81 (10%) versus 6/104 (6%). Also, time to diagnostic FNAC was significantly shorter in the SUS-FNAC group: 24.2 ± 4.5 versus 54.9 ± 11.4 days (p=0.01, unpaired t-test). Conclusion: SUS-guided FNAC for thyroid nodules is a safe and simple technique. This study demonstrates that it leads to improved patient care by reducing inadequacy rate and time to diagnosis in a low-volume thyroid center.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"13 1","pages":"21"},"PeriodicalIF":1.1,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer—What is the Optimal Treatment Approach? 非小细胞肺癌继发肾上腺少转移-最佳治疗方法是什么?

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.02.117

B. Thomsen, A. Fairchild

{"title":"Adrenal Oligometastases Secondary to Non-small Cell Lung Cancer—What is the Optimal Treatment Approach?","authors":"B. Thomsen, A. Fairchild","doi":"10.17925/OHR.2017.13.02.117","DOIUrl":"https://doi.org/10.17925/OHR.2017.13.02.117","url":null,"abstract":"Background: Five-year overall survival (OS) for patients with stage IV non-small cell lung cancer (NSCLC) is a dismal 1%. However, approximately 7% have limited or solitary metastases, including to the adrenal gland. Radical treatment of these oligometastases (OM) could increase local control and improve OS. Our objective was to critically analyze data describing aggressive treatment of adrenal OM secondary to NSCLC. Methods: A literature search examining English publications describing surgery or radiotherapy (RT) was performed, supplemented by searching reference lists. Case reports of three or fewer patients, and articles from which NSCLCor adrenal-specific clinical outcomes could not be abstracted, were excluded. Results: Twenty-nine studies met eligibility criteria (521 patients), 26 retrospective. No publications directly compare modalities. Four surgery studies described contemporaneous patients treated with palliative chemotherapy (CH) alone. Reported median OS ranged from 9.5–64 months after adrenalectomy, 8–23 months after RT, and 6–8.5 months after CH. Local failure after surgery was 14%, with response rates after RT 57–75%. Both appear well-tolerated. Conclusions: In patients with an adrenal OM secondary to NSCLC, aggressive treatment should be considered. However, due to the paucity of high quality evidence, it is unclear at present whether this approach alters the natural history of the disease.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":"13 1","pages":"117"},"PeriodicalIF":1.1,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67596810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances 非小细胞肺癌的靶向和免疫治疗最新进展

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.02.77

S. Ramalingham

引用次数: 0

Decreasing Lung Cancer Mortality through Screening—The Lung Cancer Alliance Experience 通过筛查降低肺癌死亡率-肺癌联盟的经验

IF 1.1 1区历史学

Oral History Review Pub Date : 2017-01-01 DOI: 10.17925/OHR.2017.13.01.17

L. F. Ambrose, A. Copeland, J. King

引用次数: 0